To our knowledge, this is the first clinical study to examine
the antiinflammation effect of LC supplementation in patients
with CAD. In this clinical trial, we demonstrated that LC at a dose
of 1000 mg/d for 12 wk significantly reduced the levels of
inflammation markers in patients with CAD. The levels of LC and